- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02487407
Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS)
Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension
In the double-blind, cross-over part of the study, ODM-109 capsules and placebo capsules for ODM-109 will be administered for 2 weeks separated by a 19-23 days wash-out period. During each treatment period of the double-blind cross-over part, there will be a baseline visit (day 1) and 2 visits (5 ± 2 and 14 ± 2 days) after the start of study treatment. After completing the 3rd treatment period, the subjects will continue in the open-label follow-up part for 6 months. During the open-label follow-up, visits will be at 1, 3 and 6 months. An end-of-study visit will take place 14-25 days after the last study treatment administration for each subject. The study duration will be about 13-14 weeks for the double-blind cross-over part, and about 9-10 months for the entire study including the 6 months open-label follow-up.
The number of randomised study subjects is planned to be approximately 54 in cross-over comparison. The maximum number of subjects will not exceed 70.
Primary objective is to investigate the efficacy of oral ODM-109 on respiratory function in patients with amyotrophic lateral sclerosis (ALS).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- Charité Universitätsmedizin Berlin
-
Hannover, Germany
- Medical School Hannover
-
Jena, Germany
- University Clinical Jena
-
Ulm, Germany
- University Hospital of Ulm
-
-
-
-
-
Dublin, Ireland
- Beaumont Hospital
-
-
-
-
-
Utrecht, Netherlands
- University Medical Centre Utrecht
-
-
-
-
-
Brighton, United Kingdom
- Royal Sussex County Hospital
-
Liverpool, United Kingdom
- The Walton Centre
-
London, United Kingdom
- Royal London Hospital
-
London, United Kingdom
- London Kings College Hospital
-
Sheffield, United Kingdom
- University of Sheffield
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent (IC) for participation in the study will be obtained from the subject (or from the subject's next of kin, caregiver, or other legally acceptable representative in case the study subject him/herself cannot sign the IC due to severe muscle weakness).
- Age of at least 18 years.
- Male or female subjects with diagnosis of laboratory supported probable, probable or definite ALS according to El Escorial revised criteria (Brooks BR et al., 2000). Full electromyogram (EMG) report available compatible with ALS according to an experienced neurophysiologist.
- Ability to swallow the study treatment capsules.
- An upright (sitting position) SVC between 60-90% of the predicted value for age, height and sex at screening visit.
- Normal oxygen saturation during daytime (measure of ≥ 95% when steady state has been reached with a reliable read) in sitting position measured by pulse oximetry.
- Disease duration from symptom onset (defined by first muscle weakness or dysarthria) of 12-48 months.
- Using riluzole. The dose must have been stable for at least 4 weeks prior to screening at a dose of 50 mg b.i.d.
Exclusion Criteria:
- Subject in whom other causes of neuromuscular weakness have not been excluded.
- Subject with a diagnosis of another neurodegenerative disease (e.g. Parkinson's or Alzheimer's disease).
- Assisted ventilation or gastrostomy of any type during the preceding 3 months prior to screening or predicted to be required within the randomised, double-blind cross-over part of the study.
- Recorded diagnosis or evidence of major psychiatric diagnosis, significant cognitive impairment or clinically evident dementia.
- Any major surgery within 1 month before the screening visit or patients who are scheduled for any major surgery during the planned study period.
- Potassium < 3.7 mmol/l or > 5.5 mmol/l at screening.
- Creatinine > 170 μmol/l at screening or on dialysis.
- Blood haemoglobin < 10 g/dl at screening.
- Clinically significant hepatic impairment at the discretion of the investigator.
- Women of reproductive age without a negative pregnancy test and without a commitment to using an acceptable method of barrier or hormonal contraception (e.g. condoms, diaphragms, oral contraceptives and long acting progestin agents), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are postmenopausal (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included.
- Known hypersensitivity to levosimendan.
- Administration of levosimendan within 30 days prior to screening visit.
- Patients with history of botulinum toxin treatment for any reason.
- Patients with known history of human immunodeficiency virus infection.
- History of significant arrhythmias or other cardiac events
- Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study.
- Blood donation or loss of significant amount of blood within 60 days prior to screening.
- Participation in a clinical trial with any experimental treatment within 30 days prior to the screening visit or previous participation in the present study.
- Any other condition that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ODM-109
ODM-109 capsules for oral administration
|
ODM-109 1 mg capsule for oral administration.
Other Names:
Placebo capsule for oral administration.
Other Names:
|
PLACEBO_COMPARATOR: Placebo for ODM-109
Placebo ODM-109 capsules for oral administration
|
ODM-109 1 mg capsule for oral administration.
Other Names:
Placebo capsule for oral administration.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Slow vital capacity SVC
Time Frame: 9 months
|
Pulmonary assessment
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hand grip strength and submaximal hand grip strength endurance
Time Frame: 3 months
|
Assessment
|
3 months
|
Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)
Time Frame: 3 months
|
Scales
|
3 months
|
Quality of life
Time Frame: 9 months
|
Questionnaire
|
9 months
|
Revised ALS Functional Rating Scale ALSFRS-R
Time Frame: 9 months
|
Scale
|
9 months
|
Oxygen saturation
Time Frame: 9 months
|
Assessment
|
9 months
|
The concentrations of ODM-109, OR-1855 and OR-1896
Time Frame: 3 months
|
Pharmacokinetics Blood samples.
|
3 months
|
Determination of subject's acetylation status
Time Frame: 1 day (once at baseline)
|
Pharmacogenomics Blood samples.
|
1 day (once at baseline)
|
Sniff nasal pressure SNP
Time Frame: 9 months
|
SNP will be assessed in sitting position.
SNP will be performed for 10 times.
The highest value (cmH2O) measured will be the SNP variable.
|
9 months
|
Fatigue assessment
Time Frame: 3 months
|
Visual analogue Scale VAS
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Merja Mäkitalo, CSD, Finland
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Sclerosis
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Enzyme Inhibitors
- Protective Agents
- Cardiotonic Agents
- Phosphodiesterase Inhibitors
- Phosphodiesterase 3 Inhibitors
- Simendan
Other Study ID Numbers
- 3119001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on ODM-109
-
Orion Corporation, Orion PharmaCompletedAmyotrophic Lateral SclerosisCanada, United States, Australia, Austria, United Kingdom, Germany, Finland, Spain, France, Italy, Sweden, Netherlands, Belgium, Ireland
-
Orion Corporation, Orion PharmaCompletedProstate CancerUnited States, United Kingdom, Finland, France, Estonia, Czech Republic
-
Orion Corporation, Orion PharmaEndo PharmaceuticalsCompleted
-
Orion Corporation, Orion PharmaQuotient ClinicalCompleted
-
Orion Corporation, Orion PharmaCompleted
-
RXi Pharmaceuticals, Corp.UnknownHypertrophic ScarUnited States, Honduras
-
Orion Corporation, Orion PharmaTerminatedAmyotrophic Lateral SclerosisCanada, United States, Australia, Germany, Belgium, Finland, Spain, Austria, Italy, France, Ireland, Netherlands, Sweden, United Kingdom
-
Coronado Biosciences, Inc.Unknown
-
Hunan Province Tumor HospitalCompleted
-
RXi Pharmaceuticals, Corp.UnknownAge-related Macular Degeneration | Subfoveal Choroidal Neovascularization | Subretinal Scarring | Subretinal FibrosisUnited States